AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 132 min read$NRIX

Nurix Therapeutics reports Q3 2026 revenue $673.1M, net income $549.8M and $1.1B cash

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, net income of $549.8M, and $1.1B in cash, driven by a $653.2M license payment from Roche. R&D spending decreased slightly, while G&A rose due to transaction costs. The company advanced clinical programs for bexobrutideg and NX-5948, and presented updated clinical data at EHA 2026.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Nurix Therapeutics reports Q3 2026 revenue $673.1M, net income $549.8M and $1.1B cash — source image
Source · tradingview.com
Decision brief

The 30-second read

$NRIXBullishHigh
01

Why it matters

The earnings beat and cash infusion are likely to drive short‑term buying pressure, though investors should monitor pipeline execution.

02

Market read

The surprise earnings and large partnership payment make this a high‑impact news item for NRIX and potentially for peers in the biotech space.

03

What to watch

Potential regulatory or clinical trial setbacks for other pipeline assets could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Nurix Therapeutics (NRIX) reported its Q3 2026 results, highlighting a massive license payment from Roche and a cash position exceeding $1B.

Company-level read

Ticker impact

$NRIXBullishHigh confidence
Context

Nurix Therapeutics disclosed Q3 2026 revenue of $673.1M and net income of $549.8M, driven by a $653.2M Roche license payment.

Expected impact

upward pressure as investors price in the large license payment and profit swing.

Evidence & confidence

The earnings beat prior year by orders of magnitude and include a multi‑hundred‑million cash inflow, a material catalyst for short‑term buying.

Market effects

Sector

Biotech sector may see broader uplift from a high‑margin partnership model.

Regional

US biotech investors likely react positively; limited global spillover.

Global

Modest, confined to biotech and pharma partnership dynamics.

Counterpoint

What could challenge this read

Some investors may question sustainability of one‑off license revenue and look for longer‑term pipeline risk.

Key entities

  • company
    Nurix Therapeutics

    Biotech firm reporting Q3 2026 earnings.

  • partner
    Roche

    Provided a $653.2M license payment to Nurix.

Read at source← All news

StoryNurix Therapeutics posts Q3 2026 profit on $700 million Roche upfront payment

Also covered by

5 outlets

Related articles

OCT 13
$NRIXMedAI 8/10

Nurix Therapeutics 3Q 2026: Revenue $673.1M, EPS $4.73— 10-Q Summary

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, driven by Roche license revenue. Net income was $549.8M, a $636.2M swing from a loss last year. Diluted EPS was $4.73. The company advanced clinical trials and expanded partnerships with Roche, Gilead, Sanofi, and Pfizer, receiving $1.2B to date with up to $7.2B in potential milestones and royalties.

tradingview.com2 min
OCT 13
$NRIXHighAI 8/10

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti

SEC EDGAR 8-K2 min